Products for Research Use Only
RegisterLogin

Vadimezan

CAT: 0804-HY-10964-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10964-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Vadimezan (DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
CAS Number
117570-53-3
Product Name Alternative
DMXAA; ASA-404
UNSPSC
12352005
Hazard Statement
H302, H400
Target
IFNAR; Influenza Virus; STING
Type
Reference compound
Related Pathways
Anti-infection; Immunology/Inflammation
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/DMXAA.html
Purity
99.93
Solubility
DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(O)CC1=CC=CC(C2=O)=C1OC3=C2C=CC(C)=C3C
Molecular Formula
C17H14O4
Molecular Weight
282.29
Precautions
H302, H400
References & Citations
[1]Downey CM, et al. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization. PLoS One. 2014 Jun 18;9 (6) :e99988.|[2]Shirey KA, et al. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. J Leukoc Biol. 2011 Mar;89 (3) :351-7.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3

Alternative Products

CatalogName
GP4343-5mgVadimezan
A8233-5DMXAA (Vadimezan)
S1537-01Vadimezan (DMXAA)
MBS384233-01DMXAA (ASA404, Vadimezan)
A10324-10DMXAA (ASA404, Vadimezan) 10mg

Popular Products